Fc Receptors and Pathology

  • Jean-Luc Teillaud


The considerable amount of data on soluble and membrane FcR functions accumulated during the last decade has opened the way to a detailed exploration of the role of these molecules in rodent and human pathologies. Two major aspects of the role of FcR in pathology have been investigated: on the one hand, many efforts have been devoted to the study of the genetics of FcR expression, as well as the biochemical and functional characteristics of these molecules in pathology. The level of circulating soluble FcR and the presence of anti-FcR antibodies in sera of patients with various diseases have also been evaluated. On the other hand, FcR have been viewed as exquisite target molecules for immuno-intervention, based on their ability to induce cytotoxicity (ADCC), phagocytosis, endocytosis, release of cytokines and inflammatory mediators, enhancement of antigen presentation, and anergy. This chapter presents and discusses the involvement of the three FcγR (FcγRI, CD64, FcγRII, CD32, FcγRIII, CD16) and of the low-affinity FcεR (FεRII, CD23) in pathology, as well as the potential use of these receptors for immuno-intervention.


Systemic Lupus Erythematosus Chronic Lymphocytic Leukemia Systemic Lupus Erythematosus Patient Immune Thrombocytopenic Purpura Bispecific Antibody 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Holmes KL, Palfree RGE, Hammerling U and Morse HC3d. Alleles of the Ly-17 alloantigen define polymorphisms of the murine IgG Fc receptor. Proc Natl Acad Sci USA 1985, 82:7706–10.PubMedGoogle Scholar
  2. 2.
    Hibbs ML, Hogarth PM and McKenzie IFC. The mouse Lyl7 locus identifies a polymorphism of the Fc receptor. Immunogenetics 1985; 22:335–48.PubMedGoogle Scholar
  3. 3.
    Seidin MF, Roderick TH and Paigen B. Mouse chromosome 1. Mammal Gen 1991; 1:S1–17.Google Scholar
  4. 4.
    Prins JB, Todd JA, Rodrigues NR et al. Linkage on chromosome 3 of autoimmune diabetes and defective Fc receptor for IgG in NOD mice. Science (Wash DC) 1993; 260:695–98.Google Scholar
  5. 5.
    Mock BA, Krall MM and Dosik JK. Genetic mapping of tumor susceptibility genes involved in mouse plasmacytomagenesis. Proc Natl Acad Sci USA 1993; 90:9499–503.PubMedGoogle Scholar
  6. 6.
    Heijnen LA, van Vugt MJ, Fanger NA et al. Antigen targeting to myeloid-specific human FcγRI/CD64 triggers enhanced antibody responses in transgenic mice. J Clin Invest 1996; 97:331–8.PubMedGoogle Scholar
  7. 7.
    Takai T, Ono M, Hikida M et al. Augmented humoral and anaphylactic responses in FcγRII-deficient mice. Nature (London) 1996; 379:346–9.Google Scholar
  8. 8.
    Daëron M, Malbec O, Latour S et al. Regulation of high-affinity IgE receptor-mediated mast cell activation by murine low-affinity IgG receptors. J Clin Invest 1995; 95:577–85.PubMedGoogle Scholar
  9. 9.
    Daëron M, Latour S, Malbec O et al. The same tyrosine-based inhibition motif, in the intracytoplasmic domain of FcγRIIb, regulates negatively BCR-, TCR-, and FcR-dependent cell activation. Immunity 1995; 3:635–46.PubMedGoogle Scholar
  10. 10.
    Seizinger BR, Klinger HP, Junien C et al. Report of the committee on chromosome and gene loss in human neoplasia. Cytogenet Cell Genet 1991; 58:1080–96.Google Scholar
  11. 11.
    Hoover RG, Hickman S, Gebel HM et al. Expansion of Fc receptor-bearing T lymphocytes in patients with Immunoglobulin G and Immunoglobulin A myeloma. J Clin Invest 1981; 67:308–15.PubMedGoogle Scholar
  12. 12.
    Teillaud JL, Brunati S, Elmalek M et al. Involvement of FcR+ T cells and of IgG-BF in the control of myeloma cells. Mol Immunol 1990; 27:1209–17.PubMedGoogle Scholar
  13. 13.
    Mathiot, Teillaud JL, Elmalek M et al. Correlation between soluble serum CD 16 (sCDl6) levels and disease stage in patients with multiple myeloma. J Clin Immunol 1993; 13:41–8.PubMedGoogle Scholar
  14. 14.
    Grundy HO, Peltz G, Moore KW, et al. The polymorphic Fcγ receptor II gene maps to human chromosome lq. Immunogenetics 1989; 29:331–9.PubMedGoogle Scholar
  15. 15.
    Hulett MD and Hogarth PM. Molecular basis of Fc receptor function. Adv Immunol 1994; 57:1–127.PubMedGoogle Scholar
  16. 16.
    Lanier LL, Yu G and Phillips JH. Co-association of CD3 Ç with a receptor (CD 16) for IgG Fc on human natural killer cells. Nature (London) 1989; 342:803–5.Google Scholar
  17. 17.
    Jensen JP, Hou D, Ramsburg M et al. Organization of the human T cell receptor ζ/η gene and its genetic linkage to the FcγRII-FcγRIII gene cluster. J Immunol 1992; 148:2563–71.PubMedGoogle Scholar
  18. 18.
    Le Coniat M, Kinet JP and Berger R. The human genes for the α and γ subunits of the mast cell receptor for IgE are located on human chromosome band lq23. Immunogenetics 1990; 32:183–6.PubMedGoogle Scholar
  19. 19.
    Ceuppens JL, Baroja ML, van Vaecjk F et al. A defect in the membrane expression of high affinity 72 kD Fc receptors on phagocytic cells in four healthy subjects. J Clin Invest 1988; 82:571–8.PubMedGoogle Scholar
  20. 20.
    van de Winkel JG, de Wit TP, Ernst LK et al. Molecular basis for a familial defect in phagocyte expression of IgG receptor I (CD64). J Immunol 1995; 154:2896–903.PubMedGoogle Scholar
  21. 21.
    Takai T, Li M, Sylvestre D et al. FcR γ chain deletion results in pleiotro-pic effector cell defects. Cell 1994; 76: 519–29.PubMedGoogle Scholar
  22. 22.
    Tax WJM, Willems HW, Reekers PPM et al. Polymorphism in mitoge-nic effect of IgGl monoclonal antibodies against T3 antigen on human T cells. Nature (London) 1983; 304:445–7.Google Scholar
  23. 23.
    Warmerdam PA, van de Winkel JGJ, Grosselin EJ et al. Molecular basis for a polymorphism of human FcγRII. J Exp Med 1990; 172:19–25.PubMedGoogle Scholar
  24. 24.
    Warmerdam PAM, van de Winkel JGJ, Vlug A et al. A single amino-acid in the second Ig-like domain of the human Fcγ receptor II is critical in human IgG2 binding. J Immunol 1991; 147:1338–43.PubMedGoogle Scholar
  25. 25.
    Abo T, Tilden AB, Balch CM et al. Ethnic differences in the lymphocyte proliferative response induced by a murine IgGl antibody Leu4 to T3 molecule. J. Exp. Med 1984; 160:303–9.Google Scholar
  26. 26.
    Reilly AF, Norris CF, Surrey S et al. Genetic diversity in human Fc receptor II for IgG: FcγRIIA ligand-binding polymorphism. Clin Diagnostic Lab Immunol 1994; 1:640–4.Google Scholar
  27. 27.
    Sanders LA, van de Winkel JGJ, Rijkers GT et al. FcγRIIa (CD32) heterogeneity in patients with recurrent bacterial respiratory tract infections. J Infect Diseases 1994; 170:854–61.Google Scholar
  28. 28.
    Bredius RG, Derkx BH, Fijen CA et al. FcγRIIa (CD32) polymorphism in fulminant meningococcal septic shock in children. J Infect Diseases 1994; 170:848–53.Google Scholar
  29. 29.
    van de Winkel JGJ and Capel PJA. Human IgG Fc receptor heterogeneity: molecular aspects and clinical implications. Immunol Today 1993: 14:215–21.PubMedGoogle Scholar
  30. 30.
    de Haas M, Kleijer M, van Zwieten R et al. Neutrophil FcγRIIIb deficiency, nature, and clinical consequences: a study of 21 individuals from 14 families. Blood 1995; 86:2403–13.PubMedGoogle Scholar
  31. 31.
    Minchinton RM, de Haas M, von dem Borne AE et al. Abnormal neutrophil phenotype and neutrophil FcγRIII deficiency corrected by bone marrow transplantation. Transfusion 1995; 35:874–8.PubMedGoogle Scholar
  32. 32.
    Huizinga TWJ, Kuijpers RWAM, Kleijer M et al. Maternal genomic neutrophil FcγRIII deficiency leading to neonatal isoimmune neutropenia. Blood 1990; 76:1927–32.PubMedGoogle Scholar
  33. 33.
    Stroncek DF, Skubitz KM, Plachta LB et al. Alloimmune neonatal neutropenia due to an antibody to the neutrophil FcγRIII with maternal deficiency of CD 16 antigen. Blood 1991; 77:1572–80.PubMedGoogle Scholar
  34. 34.
    Fromont P, Bettaieb A, Skouri H et al. Frequency of the polymorphonuclear neutrophil FcγRIII deficiency in the French population and its involvement in the development of neonatal alloimmune neutropenia. Blood 1992; 79:2131–4.PubMedGoogle Scholar
  35. 35.
    Cartron J, Celton JL, Gane P et al. Iso-immune neonatal neutropenia due to an anti-FcγRIII (CD 16) antibody. Eur J Ped 1992; 151:438–41.Google Scholar
  36. 36.
    Puig N, de Haas M, Kleijer M et al. Isoimmune neonatal neutropenia caused by FcγRIIIb antibodies in a Spanish child. Transfusion 1995; 35:683–7.PubMedGoogle Scholar
  37. 37.
    Clark MR, Liu L, Clarkson SB et al. An abnormality of the gene that encodes neutrophil FcγRIII in a patient with systemic lupus erythematosus. J Clin Invest 1990; 86:341–6.PubMedGoogle Scholar
  38. 38.
    Selvaraj P, Rosse WF, Silber R et al. The major Fc receptor in blood has a phosphatidylinositol anchor and is deficient in paroxysmal nocturnal hemoglobinuria. Nature (London) 1988; 333:565–7.Google Scholar
  39. 39.
    Huizinga TWJ, Kleijer M, Roos D et al. Differences between FcγRIII of human neutrophils and human K/NK lymphocytes in relation to the NA antigen system. In: Knapp W et al, eds. Leucocyte Typing. Oxford: Oxford University Press, 1989:582–85.Google Scholar
  40. 40.
    Bredius RG, Fijen CA, de Haas M et al. Role of neutrophil FcγRIIa (CD32) and FcγRIIIb (CD 16) polymorphic forms in phagocytosis of human IgGl- and IgG3-opsonized bacteria and erythrocytes. Immunol 1994; 83:624–30.Google Scholar
  41. 41.
    Ory PA, Goldstein IA, Kwoh EE et al. Characterization of polymorphic forms of FcγRIII on human neutrophils. J Clin Invest 1989; 83:1676–81.PubMedGoogle Scholar
  42. 42.
    Ravetch JV and Perussia B. Alternative membrane forms of FcγRIII (CD 16) on human NK cells and neutrophils: cell-type specific expression of two genes which differ in single nucleotide substitution. J Exp Med 1989; 170:481–91.PubMedGoogle Scholar
  43. 43.
    Lalezari P. Granulocyte antigen systems. In: Engelfriet CP et al, eds. Immunohaematology. Amsterdam: Elsevier, 1984:33.Google Scholar
  44. 44.
    Amigorena S, Bonnerot C, Drake J et al. Cytoplasmic domain heterogeneity and functions of IgG Fc receptors in B lymphocytes. Science (Wash DC) 1992; 256:1808–12.Google Scholar
  45. 45.
    Debets JMH, van de Winkel JGJ, Ceuppens JL et al. Crosslinking of both FcγRI and FcγRII induces secretion of tumor necrosis factor by human monocytes, requiring high-affinity Fc-FcγR interactions. J Immunol 1990; 144:1304–10.PubMedGoogle Scholar
  46. 46.
    Simms HH, Gaither TA, Fries LF et al. Monokines released during short term Fcγ receptor phagocytosis up-regulate polymorphonuclear leukocytes and mono-phagocytic function. J Immunol 1991; 147:265–72.PubMedGoogle Scholar
  47. 47.
    Krutmann J, Kirnbauer R, Kock A et al. Crosslinking Fc receptors on monocytes triggers IL-6 production. J Immunol 1990; 145:1337–42.PubMedGoogle Scholar
  48. 48.
    Anegon I, Cuturi MC, Trinchieri G et al. Interaction of Fc receptor (CD 16) ligands induces transcription of interleukin 2 receptor (CD25) and lymphokine genes and expression of their products in human natural killer cells. J Exp Med 1988; 167:452–72.PubMedGoogle Scholar
  49. 49.
    Anderson CL, Guyre PM, Whitin JC et al. Monoclonal antibodies to Fc receptors for IgG on human mononuclear phagocytes: antibody characterization and induction of superoxyde production in a monocyte cell. J Biol Chem 1986; 261:12856–64.PubMedGoogle Scholar
  50. 50.
    Willis HE, Browder B, Feister AJ et al. Monoclonal antibody to human IgG Fc receptors: cross-linking of receptors induces lysosomal enzyme release and superoxyde generation by neutrophils. J Immunol 1988; 140:234–9.PubMedGoogle Scholar
  51. 51.
    Tosi MF and Berger M. Functionnal differences between the 40 kDa and 50 to 70 kDa IgG Fc receptors on human neutrophils revealed by elastase treatment and antireceptors antibodies. J Immunol 1988; 141:2097–2103.PubMedGoogle Scholar
  52. 52.
    Daëron M, Bonnerot C, Latour S et al. Murine recombinant FcγRIII, but not FcγRII, trigger sertonin release in rat basophilic leukemia cells. J Immunol 1992; 149:1365–73.PubMedGoogle Scholar
  53. 53.
    Trezzini C, Jungi TW, Spycher MO et al. Human monocyte CD36 and CD 16 are signalling molecules. Immunol 1990; 71:29–37.Google Scholar
  54. 54.
    Edberg JC and Kimberly RP. Modulation of Fcγ and complement receptor function by the glycosylphosphatidylinositol-anchored form of FcγRIII. J Immunol 1994; 152:5826–35.PubMedGoogle Scholar
  55. 55.
    Almon RR, Andrew CG and Appel SH. Serum globulin in myasthenia gravis: inhibition of alpha-bungarotoxin binding to acetylcholine receptors. Science (Wash DC) 1974; 186:55–7.Google Scholar
  56. 56.
    Boros P, Chen J, Bona C et al. Autoimmune mice make anti-Fcγ receptor Ig. J Exp Med 1990; 171:1581–95.PubMedGoogle Scholar
  57. 57.
    Russell PJ and Steinberg AD. Studies of peritoneal macrophage function in mice with systemic lupus erythematosus: depressed phagocytosis of opsonised sheep erythrocytes in vitro. Clin Immunol Immunopathol 1983; 27:387–402.PubMedGoogle Scholar
  58. 58.
    Boros P, Odin JA, Muryoi T et al. IgM anti-FcγR autoantibodies trigger neutrophil degranulation. J Exp Med 1991; 173:1473–82.PubMedGoogle Scholar
  59. 59.
    Szegedi A, Boros P, Chen J et al. An FcγRIII (CD16)-specific autoantibody from a patient with progressive systemic sclerosis. Immunol Lett 1993; 35:69–76.PubMedGoogle Scholar
  60. 60.
    Sipos A, Csortos C, Sipka S et al. The antigen/receptor specificity of antigranulocyte antibodies in patients with SLE. Immunol Lett 1988; 19:329–34.PubMedGoogle Scholar
  61. 61.
    Davis K, Boros P, Keltz M et al. Circulating FcγR-specific autoantibodies in localized and systemic scleroderma. J Am Acad Dermatol 1995; 33:612–6.PubMedGoogle Scholar
  62. 62.
    Boros P, Muryoi T, Spiera H et al. Autoantibodies directed against different classes of FcγR are found in sera of autoimmune patients. J Immunol 1993; 150:2018–24.PubMedGoogle Scholar
  63. 63.
    Boros P, Odin JA, Chen J et al. Specificity and class distribution of FcγR-specific autoantibodies in patients with autoimmune disease. J Immunol 1994; 152:302–6.PubMedGoogle Scholar
  64. 64.
    Fridman WH and Golstein P. Immunoglobulin-Binding Factor present on and produced by thymus-processed lymphocytes (T cells). Cell Immunol 1974; 11:442–5.PubMedGoogle Scholar
  65. 65.
    Fridman WH, Rabourdin-Combe C, Neauport-Sautès C et al. Characterization and function of T cell Fcγ receptor. Immunol Rev 1981; 56:51–88.PubMedGoogle Scholar
  66. 66.
    Fridman WH. Fc receptors and immunoglobulin binding factors. FASEB J 1991; 5:2684–90.PubMedGoogle Scholar
  67. 67.
    Teillaud JL, Bouchard C, Astier A et al. Natural and recombinant soluble low-affinity FcγR: detection, purification, and functional activities. Immunometh 1994; 4:48–64.Google Scholar
  68. 68.
    Khayat D, Dux Z, Anavi R et al. Circulating cell free Fcγ2b/γl receptor in normal mouse serum: its detection and specificity. J Immunol 1984; 132:2496–501.PubMedGoogle Scholar
  69. 69.
    Pure E, Durie CJ, Summerill CK et al. Identification of soluble Fc receptors in mouse serum and the conditioned medium of stimulated B cells. J Exp Med 1984; 160:1836–49.PubMedGoogle Scholar
  70. 70.
    Khayat D, Geffrier C, Yoon S et al. Soluble circulating Fcγ receptors in human serum: a new ELISA assay for specific and quantitative detection. J Immunol Meth 1987; 100:235–41.Google Scholar
  71. 71.
    Fridman WH, Mathiot C, Moncuit J et al. Fc receptors, immunoglobu-lin-binding factors and B chronic lymphocytic leukemia. Nouv Rev Franc Hematol 1988; 30:311–5.Google Scholar
  72. 72.
    Huizinga TWM, van der Schoot CE, Jost C et al. The PI-linked receptor FcRIII is released on stimulation of neutrophils. Nature (London) 1988; 333:667–9.Google Scholar
  73. 73.
    Lanier LL, Phillips JH and Testi R. Membrane anchoring and spontaneous release of CD 16 (FcRIII) by natural killer cells and granulocytes. Eur J Immunol 1989; 19:775–8.PubMedGoogle Scholar
  74. 74.
    de Haas M, Kleijer M, Minchinton RM et al. Soluble FcγRIIIa is present in plasma and is derived from natural killer cells. J Immunol 1994; 152:900–7.PubMedGoogle Scholar
  75. 75.
    Sautès C, Teillaud C, Mazières N et al. Soluble FcγR (sFcγR): detection in biological fluids and production of a murine recombinant sFcγR biologically active in vitro and in vivo. Immunobiol 1992; 185:207–221.Google Scholar
  76. 76.
    Esposito-Farese ME, Sautès C, de la Salle H et al. Membrane and soluble FcγRII/III modulate the antigen-presenting capacity of murine dendritic epidermal Langerhans cells for IgG-complexed antigens. J Immunol 1995; 154:1725–36.Google Scholar
  77. 77.
    Gisler RH and Fridman WH. Suppression of in vitro antibody synthesis by immunoglobulin-binding factor. J Exp Med 1975; 142:507–11.PubMedGoogle Scholar
  78. 78.
    Varin N, Sautès C, Galinha A et al. Recombinant soluble receptors for the Fcγ portion inhibit antibody production in vitro. Eur J Immunol 1989; 19:2263–8.PubMedGoogle Scholar
  79. 79.
    Suemura M, Ishizaka A, Kobatake S et al. Inhibition of IgE production in hybridomas by the IgE class specific suppressor factor from T hybrido-mas. J Immunol 1983; 130:1056–60.PubMedGoogle Scholar
  80. 80.
    Simpson SD, Snider DP, Zettel LA et al. Soluble FcR block suppressor T cell activity at low concentration in vitro allowing isotype-specific antibody production. Cell Immunol 1996; 167:122–8.PubMedGoogle Scholar
  81. 81.
    Brunati S, Moncuit J, Fridman WH et al. Regulation of IgG production by suppressor FcγRII+ T hybridomas. Eur J Immunol 1990; 20:55–61.PubMedGoogle Scholar
  82. 82.
    Müller S and Hoover RG. T cells with Fc receptors in myeloma; suppression of growth and secretion of MOPC315 by Ta cells. J Immunol 1985; 134:644–7.PubMedGoogle Scholar
  83. 83.
    Teillaud C, Galon J, Zilber MTh et al. Soluble CD 16 binds peripheral blood mononuclear cells and inhibits pokeweed-mitogen-induced responses. Blood 1993; 82:3081–90.PubMedGoogle Scholar
  84. 84.
    Gordon J, Flores-Romo L, Cairns JA et al. CD23: a multi-functional receptor lymphokine ? Immunol Today 1989; 10:153–7.PubMedGoogle Scholar
  85. 85.
    Bouchard C, Galinha A, Tartour E et al. A Transforming Growth Factor β-like immmunosuppressive factor in Immunoglobulin G-Binding Factor. J Exp Med 1995; 182:1717–26.PubMedGoogle Scholar
  86. 86.
    Aubry JP, Pochon S, Graber P et al. CD21 is a ligand for CD23 and regulates IgE production. Nature (London) 1992; 358:505–7.Google Scholar
  87. 87.
    Armant M, Rubio M, Delespesse G et al. Soluble CD23 directly activates monocytes to contribute to the antigen-independent stimulation of resting T cells. J Immunol 1995; 155:4868–75.PubMedGoogle Scholar
  88. 88.
    Zhou MJ, Todd III RF, van de Winkel JGJ et al. Cocapping of the leukoadhesin molecules CR3 and LFA-1 with FcγRIII on human neutrophils. Possible role of lectin-like interactions. J Immunol 1993; 150:3030–41.PubMedGoogle Scholar
  89. 89.
    Galon J, Bouchard C, Fridman WH et al. Ligands and biological activities of soluble Fcγ receptors. Immunol Lett 1995; 44:175–81.PubMedGoogle Scholar
  90. 90.
    Galon J, Gauchat J-F, Mazières N et al. Soluble Fcγ receptor type III (FcγRIII, CD 16) triggers cell activation through interaction with complement receptors. J Immunol 1996; 157:1184–1192.PubMedGoogle Scholar
  91. 91.
    Daëron M, Sautès C, Bonnerot C et al. Murine type II Fcγ receptors and IgG binding factors. Chem Immunol 1989; 47:21–78.PubMedGoogle Scholar
  92. 92.
    Araujo Jorge T, El Bouhdidi A, Rivera MT et al. Trypanosoma cruzi infection in mice enhances the membrane expression of low-affinity Fc receptors for IgG and the release of their soluble forms. Paras Immunol 1993; 15:539–46.Google Scholar
  93. 93.
    Fridman WH, Gresser I, Bandu M-T et al. Interferon enhances the expression of Fcγ receptors. J Immunol 1980; 124:2436–41.PubMedGoogle Scholar
  94. 94.
    Guyre PM, Morganelli PM and Miller R. Recombinant immune interferon increases immunoglobulin G Fc receptors on cultured human mononuclear phagocytes. J Clin Invest 1983; 72:393–7.PubMedGoogle Scholar
  95. 95.
    de la Salle C, Esposito-Farese ME, Bieber Th et al. Release of soluble FcγRII/CD32 molecules by human Langerhans cells: a subtle balance between shedding and secretion? J Invest Dermatol 1992; 99:15S–17S.PubMedGoogle Scholar
  96. 96.
    Harrison D, Phillips JH and Lanier LL. Involvement of a metalloprotease in spontaneous and phorbol ester-induced release of natural killer cell-associated FcγRIII (CD16). J Immunol 1991; 147:3459–65.PubMedGoogle Scholar
  97. 97.
    Bazil V and Strominger JL. Metalloprotease and serine protease are involved in cleavage of CD43, CD44, and CD 16 from stimulated human granulocytes. Induction of cleavage of L-selectin via CD 16. J Immunol 1994; 152:1314–22.PubMedGoogle Scholar
  98. 98.
    Lynch A, Tartour E, Teillaud JL et al. Increased levels of soluble low-affinity Fcγ receptors (IgG-Binding Factors) in the sera of tumor-bearing mice. Clin Exp Immunol 1992; 87:208–14.PubMedGoogle Scholar
  99. 99.
    Ran M, Katz B, Kimchi N et al. The in vivo acquisition of FcγRII expression on polyoma virus transformed cells derived from tumors of long latency. Cancer Res 1991; 51:612–8.PubMedGoogle Scholar
  100. 100.
    Ben-Baruch Langer A, Emmanuel A, Even J et al. Phenotypic properties of 3T3 cells transformed in vitro with polyoma virus and passaged once in syngeneic animals. J Immunobiol 1992; 185:281–91.Google Scholar
  101. 101.
    Zusman T, Gohar O, Eliassi I et al. The murine Fc-gamma (Fcγ) receptor type II Bl is a tumorigenicity-enhancing factor in polyoma-virus-trans-formed 3T3 cells. Int J Cancer 1996; 65:221–9.PubMedGoogle Scholar
  102. 102.
    Huizinga TW, de Haas M, van Oers MH et al. The plasma concentration of soluble FcγRIII is related to production of neutrophils. Brit J Hsematol 1994; 87:459–63.Google Scholar
  103. 103.
    de Haas M, Kleijer M, Minchinton RM et al. Soluble FcγRIIIa is present in plasma and is derived from natural killer cells. J Immunol 1994; 152:900–7.PubMedGoogle Scholar
  104. 104.
    Khayat D, Soubrane C, Andrieu JM et al. Changes of soluble CD 16 levels in serum of HIV-infected patients: correlation with clinical and biologic prognostic factors. J Inf Dis 1990; 161:430–5.Google Scholar
  105. 105.
    Boros P, Gardos E, Bekesi GJ et al. Change in expression of FcγRIII (CD 16) on neutrophils from human immunodeficiency virus-infected individuals. Clin Immunol Immunopath 1990; 54:281–9.Google Scholar
  106. 106.
    van der Herik-Oudijk IE, Westerdaal NAC, Henriquez NV et al. Functional analysis of human FcγRII (CD32) isoforms expressed in B lymphocytes. J Immunol 1994; 152:574–85.Google Scholar
  107. 107.
    Fleit HB and Kobasiuk CD. Soluble FcγRIII is present in lower concentrations in the serum of patients with acute myelogenous leukemia (AML): a retrospective study. Leukemia 1993; 7:1250–2.PubMedGoogle Scholar
  108. 108.
    Hutin P, Lamour A, Pennec YL et al. Cell-free FcγRIII in sera from patients with systemic lupus erythematosus: correlation with clinical and biological features. Int Arch Allerg Immunol 1994; 103:23–7.Google Scholar
  109. 109.
    Lamour A, Soubrane C, Ichen M et al. FcγRIII shedding by polymorphonuclear cells in primary Sjögren’s syndrome. Eur J Clin Invest 1993; 23:97–101.PubMedGoogle Scholar
  110. 110.
    Lamour A, Baron D, Soubrane C et al. Anti-FcγRIII autoantibody is associated with soluble receptor in rheumatoid arthritis serum and synovial fluid. J Autoimmun 1995; 8:249–65.PubMedGoogle Scholar
  111. 111.
    Fleit HB, Kobasiuk CD, Daly C et al. A soluble form of FcγRIII is present in human serum and other body fluids and is elevated at sites of inflammation. Blood 1992; 79:2721–8.PubMedGoogle Scholar
  112. 112.
    Ierino FL, Powell MS, McKenzie IF et al. Recombinant soluble human FcγRII: production, characterization, and inhibition of the Arthus reaction. J Exp Med 1993; 178:1617–28.PubMedGoogle Scholar
  113. 113.
    Gavin AL, Wines BD, Powell MS et al. Recombinant soluble FcγRII inhibits immune complex precipitation. Clin Exp Immunol 1995; 102:620–5.PubMedGoogle Scholar
  114. 114.
    Teillaud C, Jourde M, Sautès C et al. Acute periodontitis and soluble CD32 and CD 16 levels in saliva. J Parodontol 1993; 12:9–18.Google Scholar
  115. 115.
    Sedor J, Callahan HJ, Perussia B et al. Soluble FcγRIII (CD 16) and IgG levels in seminal plasma of men with immunological infertility. J Androl 1993; 14:187–93.PubMedGoogle Scholar
  116. 116.
    Delespesse G, Sarfati M and Hofstetter H. Human IgE-binding factors. Immunol Today 1989; 10:159–64.PubMedGoogle Scholar
  117. 117.
    Sarfati M, Bron D, Lagneaux L et al. Elevation of IgE binding factors in serum of patients with B cell-derived chronic lymphocytic leukemia. Blood 1988; 71:94–8.PubMedGoogle Scholar
  118. 118.
    Sarfati M. CD23 and chronic lymphocytic leukemia. Blood Cells 1993; 19:591–6.PubMedGoogle Scholar
  119. 119.
    Fournier S, Delespesse G, Rubio M et al. CD23 antigen regulation and signaling in chronic lymphocytic leukemia. J Clin Invest 1992; 89:1312–21.PubMedGoogle Scholar
  120. 120.
    Fournier S, Yang LP, Delespesse G et al. The two CD23 isoforms display differential regulation in chronic lymphocytic leukæmia. Br J Hæmatol 1995; 89:373–9.PubMedGoogle Scholar
  121. 121.
    Yawetz S, Cumberland WG, van der Meyden M et al. Elevated serum levels of soluble CD23 (sCD23) precede the appearance of acquired immunodeficiency syndrome-associated Non-Hodgkin’s Lymphoma. Blood 1995; 85:1843–9.PubMedGoogle Scholar
  122. 122.
    Kim KM, Nanbu M, Iwai Y et al. Soluble low affinity Fc receptor for IgE in the serum of allergic and nonallergic children. Pediatr Res 1989; 26:49–53.PubMedGoogle Scholar
  123. 123.
    Yanagihara Y, Sarfati M, Marsh D et al. Serum levels of IgE-binding factor (soluble CD23) in diseases associated with elevated IgE. Clin Exp Allergy 1990; 20:395–401.PubMedGoogle Scholar
  124. 124.
    Bansal A, Roberts T, Hay EM et al. Soluble CD23 levels are elevated in the serum of patients with primary Sjögren’s syndrome and systemic lupus erythematosus. Clin Exp Immunol 1992; 89:452–5.PubMedGoogle Scholar
  125. 125.
    Bansal AS, Ollier W, Marsh MN et al. Variations in serum sCD23 in conditions with either enhanced humoral or cell-mediated immunity. Immunology 1993; 79: 285–9.PubMedGoogle Scholar
  126. 126.
    Chomarat P, Briolay J, Banchereau J et al. Increased production of soluble CD23 in rheumatoid arthritis, and its regulation by interleukin-4. Arthritis and Rheumat 1993; 36:234–42.Google Scholar
  127. 127.
    Yoshikawa T, Nanba T, Kato H et al. Soluble FcεRII/CD23 in patients with autoimmune diseases and Epstein-Barr virus-related disorders: analysis by ELISA for soluble FcεRII/CD23. Immunomethods 1994; 4:65–71.PubMedGoogle Scholar
  128. 128.
    Bansal AS, MacGregor AJ, Pumphrey RS et al. Increased levels of sCD23 in rheumatoid arthritis are related to disease status. Clin Exp Rheumatol 1994; 12:281–5.PubMedGoogle Scholar
  129. 129.
    Gavin AL, Snider J, Hulett MD et al. Expression of recombinant soluble FcERI: function and tissue distribution studies. Immunology 1995; 86:392–8.PubMedGoogle Scholar
  130. 130.
    Imbach P, Barandun S, d’Apuzzo V et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in chilhood. Lancet 1981; i: 1228–31.Google Scholar
  131. 131.
    Ferh J, Hofmann V, Kappeler U. Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high dose intravenous gammma globulin. N Engl J Med 1982; 306:1254–8.Google Scholar
  132. 132.
    Salama A, Mueller-Eckhardt C, Fiefel V. Effect of intravenous immunoglobulin in immune thrombocytopenia; competitive inhibition of reticuloendothelial system function by sequestration of autologous red blood cells. Lancet 1983; ii:193–5.Google Scholar
  133. 133.
    Clarkson S, Bussel J, Kimberly R et al. Treatment of refractory immune thrombocytopenic purpura with an anti-Fcγ receptor antibody. N Engl J Med 1986; 314:1236–9.PubMedGoogle Scholar
  134. 134.
    Bussel J. Modulation of Fc receptor clearance and antiplatelet antibodies as a consequence of intravenous immune globulin infusion in patients with immune thrombocytopenic purpura. J Allergy Clin Immunol 1989; 84:566–78.PubMedGoogle Scholar
  135. 135.
    Soubrane C, Tourani JM, Andrieu JM et al. Biologic response to anti-CD 16 monoclonal antibody therapy in a human immunodeficiency virus-related immune thrombocytopenic purpura patient. Blood 1993; 81:15–9.PubMedGoogle Scholar
  136. 136.
    Kaveri SV, Dietrich G, Hurez V et al. Intravenous immunoglobulins (IVIg) in the treatment of autoimmune disease. Clin Exp Immunol 1991; 86:192–8.PubMedGoogle Scholar
  137. 137.
    Debré M, Bonnet M-C, Fridman WH et al. Infusion of Fcγ fragments for treatment of children with acute immune thrombocytopenic purpura. Lancet 1993; 342:945–9.PubMedGoogle Scholar
  138. 138.
    Laporte J-Ph, Mathiot C, Teillaud J-J et al. Intravenous injection of polyclonal human IgG as treatment of refractory Multiple Myeloma. Blood 1990; 76 Suppl I:359a.Google Scholar
  139. 139.
    Vervoordeldonk SF, Merle PA, van Leeuwen EF et al. FcγRII (CD32) on malignant B cells influences modulation induced by anti-CD 19 monoclonal antibody. Blood 1994; 83:1632–9.PubMedGoogle Scholar
  140. 140.
    Slupsky JR, Cawley JC, Griffith LS et al. Role of FcγRII in platelet activation by monoclonal antibodies. J Immunol 1992; 148:3189–94.PubMedGoogle Scholar
  141. 141.
    Worthington RE, Carroll RC, Boucheix C. Platelet activation by CD9 monoclonal antibodies is mediated by the FcγII receptor. Br J Hæmatol 1990; 74:216–22.PubMedGoogle Scholar
  142. 142.
    Gachet C, Astier A, de la Salle H et al. Release of FcγRIIa2 by activated platelets and inhibition of anti-CD9-mediated platelet aggregation by recombinant FcγRIIa2. Blood 1995; 85:698–704.PubMedGoogle Scholar
  143. 143.
    Alegre ML, Tso JY, Sattar H et al. An anti-murine CD3 monoclonal antibody with a low affinity for Fcγ receptors suppresses transplantation responses while minimizing acute toxicity and immunogenicity. J Immunol 1995; 155:1544–55.PubMedGoogle Scholar
  144. 144.
    Vossen AC, Tibbe GJ, Kroos MJ et al. Fc receptor binding of anti-CD3 monoclonal antibodies is not essential for immunosuppression, but triggers cytokine-related side effects. Eur J Immunol 1995; 25:1492–6.PubMedGoogle Scholar
  145. 145.
    Contreras M and de Silva M. The prevention and management of hæmolytic disease of the newborn. J Roy Soc Med 1994; 87:256–8.PubMedGoogle Scholar
  146. 146.
    de la Camara C, Arrieta R, Gonzalez A et al. High-dose intravenous immunoglobulin as the sole prenatal treatment for severe Rh immunization. N Engl J Med 1988; 318:519–20.PubMedGoogle Scholar
  147. 147.
    Phillips NE and Parker DC. Fc-dependent inhibition of mouse B cell activation by whole anti-μ antibodies. J Immunol 1983;130:602–6.PubMedGoogle Scholar
  148. 148.
    Phillipps NE and Parker DC. Cross-linking of B lymhocyte Fcγ receptors and membrane immunoglobulin inhibits anti-immunoglobulin-induced blastogenesis. J Immunol 1984; 132:627–32.Google Scholar
  149. 149.
    Fanger MW, Graziano RF and Guyre PM. Production and use of anti-FcR bispecific antibodies. Immunomethods 1994; 4:72–81.PubMedGoogle Scholar
  150. 150.
    Howell AL, Guyre PM, You K et al.Targeting HIV-1 to FcγR on human phogocytes via bispecific antibodies reduces infectivity of HIV-1 to T cells. J Leuk Biol 1994; 55:385–91.Google Scholar
  151. 151.
    Homsy J, Meyer M, Tateno M et al. The Fc and not CD4 receptor mediates antibody enhancement of HIV infection in human cells. Science (Wash DC) 1989; 244:1357–60.Google Scholar
  152. 152.
    Valone FH, Kaufman PA, Guyre PM et al. Phase la/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene Her-2/neu. J Clin Oncol 1995; 13:2281–92.PubMedGoogle Scholar
  153. 153.
    Weiner LM, Clark JI, Davey M et al. Phase I trial of 2B1, a bispecifïc monoclonal antibody targeting c-erb-2 and FcγRIII. Cancer Res 1995; 55:4586–93.PubMedGoogle Scholar
  154. 154.
    Graziano RF, Tempest PR, White P et al. Construction and characterization of a humanized anti-FcγRI monoclonal antibody. J Immunol 1995; 155:4996–5002.PubMedGoogle Scholar
  155. 155.
    Repp R, Valerius T, Wieland G et al. G-CSF-stimulated PMN in immunotherapy of breast cancer with a bispecifïc antibody to FcγRI and to Her-2/neu. J Hematother 1995; 4:415–21.PubMedGoogle Scholar
  156. 156.
    Michon J, Moutel S, Barbet J et al. In vitro killing of neuroblastoma cells by neutrophils derived from granulocyte colony-stimulating factor-treated cancer patients using an anti-disialoganglioside/anti-FcγRI bispecifïc antibody. Blood 1995; 86:1124–30.PubMedGoogle Scholar
  157. 157.
    Heijnen IA, van Vugt MJ, Fanger M et al. Antigen targeting to myeloid-specific human FcγRI/CD64 triggers enhanced antibody responses in transgenic mice. J Clin Invest 1996; 97:331–8.PubMedGoogle Scholar
  158. 158.
    Helm B, Kebo D, Vercelli D et al. Blocking of passive sensitization of human mast cells and basophil granulocytes with IgE antibodies by a recombinant human ε chain fragment of 76 amino acids. Proc Natl Acad Sci (USA) 1989; 86:9465–9.Google Scholar
  159. 159.
    Plater-Zyberk C and Bonnefoy J-Y. Marked amelioration of established collagen-induced arthritis by treatment with antibodies to CD23 in vivo. Nature Med (London) 1995; 1:781–5.Google Scholar

Copyright information

© R.G. Landes Company 1997

Authors and Affiliations

  • Jean-Luc Teillaud

There are no affiliations available

Personalised recommendations